Late preterm infants are typically born between 34 weeks and 36 weeks plus six days of gestation. They often appear stronger and more mature than very preterm babies, but their brains, hormone systems and feeding abilities are still developing. After birth, glucose levels can drop as the infant transitions from a constant placental supply to intermittent feeding. Immature glycogen stores, limited fat reserves, difficulty coordinating sucking and swallowing, and illness-related stress can all increase the risk of hypoglycemia.

Glucose is the brain’s primary energy source during early life, making neonatal hypoglycemia biologically concerning. When glucose delivery falls, the brain may initially compensate by using alternative fuels, including lactate and ketone bodies. If the shortage is severe, prolonged or repeatedly missed, however, energy production can become insufficient. This may interfere with neuronal signaling and, in extreme cases, contribute to cellular injury. The challenge is that many affected newborns show no obvious symptoms, while symptomatic infants may display only subtle signs such as jitteriness, poor feeding, lethargy, temperature instability or apnea.

The article by U. Felderhoff-Müser focuses attention on a crucial gap between immediate treatment and long-term certainty. Hospitals commonly screen infants considered vulnerable to hypoglycemia, including late preterm newborns, and intervene with feeding, buccal dextrose gel or intravenous glucose when indicated. These measures are designed to restore glucose quickly and prevent neurological stress. Yet the threshold used to define hypoglycemia is not a universal biological line. It is a clinical value shaped by gestational age, postnatal age, symptoms, measurement method and the balance between avoiding harm and preventing unnecessary intervention.

That uncertainty has made long-term follow-up essential. Researchers have investigated whether neonatal hypoglycemia is associated with later problems involving cognition, executive function, attention, language, motor coordination and school performance. Some studies have reported higher risks after severe, recurrent or prolonged episodes, while others have found limited or inconsistent effects, particularly when low glucose was detected and treated promptly. The differences may reflect more than glucose itself: prematurity, fetal growth restriction, maternal diabetes, infection, respiratory illness and socioeconomic conditions can independently influence neurodevelopment.

This is one reason the evidence remains difficult to interpret. Most long-term studies are observational, meaning researchers cannot randomly assign infants to experience different glucose levels. Instead, they compare children who had hypoglycemia with those who did not, while attempting to account for other medical and social factors. Even sophisticated statistical adjustments may not eliminate hidden confounding. In addition, studies use different definitions of hypoglycemia, different monitoring schedules and different ages or tools for developmental testing, making direct comparisons challenging.

The timing and pattern of low glucose may be as important as the lowest recorded number. A single short episode may carry a different biological significance from repeated episodes or an extended period below a treatment threshold. Continuous glucose monitoring has raised further questions by revealing fluctuations that intermittent heel-stick testing can miss, although sensor accuracy in newborns and the clinical meaning of every detected dip are still being evaluated. The emerging picture is therefore more complex than a simple division between “normal” and “abnormal.”

For clinicians and families, the practical message is not to dismiss hypoglycemia or to assume that every low reading predicts disability. Instead, the long-term evidence supports careful surveillance of infants at risk, rapid confirmation of abnormal results, and treatment strategies that protect the brain without disrupting feeding or exposing babies to unnecessary interventions. Developmental follow-up may be particularly important for infants with severe or recurrent episodes, neurological symptoms, or multiple additional risk factors. Such monitoring can identify difficulties early, when speech, occupational or educational support may have the greatest effect.

The discussion also underscores the need for better research. Future studies will need standardized glucose definitions, precise records of duration and recurrence, improved measurement technologies and follow-up extending into school age and adolescence. Researchers must also distinguish the effects of hypoglycemia from the conditions that caused it and examine outcomes beyond a single global developmental score. Felderhoff-Müser’s review places late preterm hypoglycemia in that broader scientific context: a common neonatal event whose immediate management is well established, but whose long-term consequences still demand careful, nuanced investigation.

Subject of Research: Late preterm hypoglycemia and its long-term neurodevelopmental evidence

Article Title: Late preterm hypoglycemia through the lens of long-term evidence

Article References: Felderhoff-Müser, U. “Late preterm hypoglycemia through the lens of long-term evidence.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05316-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-05316-6

Keywords: late preterm infants, neonatal hypoglycemia, blood glucose, neurodevelopment, brain health, newborn care, long-term outcomes

Preterm infants, distinguished by their physiologic immaturity and vulnerability, present a unique challenge in neonatal neurology. The review pooled data from 14 studies encompassing 132 cases of PAIS and 57 cases of CSVT, revealing that the incidence of both conditions escalates inversely with gestational age. This finding underscores the heightened susceptibility of extremely premature neonates to cerebrovascular insults—a vulnerability likely rooted in fragile cerebral vasculature, disturbances in coagulation pathways, and systemic morbidities common in this population. The increased occurrence of these strokes in the earliest gestational ages demands urgent attention to refine diagnostic vigilance and preventive strategies targeted at the highest-risk preterm infants.

Diverging somewhat from term neonates, preterm infants with PAIS exhibited distinct risk factor profiles, with the review highlighting the notable association of twin-to-twin transfusion syndrome, which complicates monochorionic twin pregnancies by disrupting synchronized blood supply and inducing ischemic injury. Additionally, fetal heart rate abnormalities emerged as a significant precursor, often reflecting intrauterine distress that may precipitate cerebral hypoperfusion. Neonatal hypoglycemia—a metabolic imbalance notorious for exacerbating neuronal injury—also featured prominently among the risk factors predisposing preterm infants to arterial ischemic events. Together, these findings elucidate a multifactorial risk landscape that intertwines obstetric, fetal, and neonatal vulnerabilities specifically tailored to preterm physiology.

A prominent insight from the review concerns the neuroanatomical patterns of injury. Perforator artery strokes dominated PAIS cases in preterm infants. These small, penetrating arteries supply critical deep brain structures and their occlusion portends devastating neurological sequelae. In parallel, CSVT in this population showed a strong predilection for the transverse sinus, a major venous drainage pathway in the brain. Thrombosis in this sinus can precipitate venous congestion, hemorrhagic transformation, and global cerebral dysfunction. These anatomic patterns, identifiable via advanced neuroimaging techniques such as MRI and MR venography, provide crucial diagnostic clues, enabling differentiation of these pathologies from other causes of neonatal encephalopathy.

Neuroimaging, a cornerstone in the early diagnosis of neonatal stroke, often exhibits subtleties in preterm infants due to their ongoing cerebral maturation and the frequent coexistence of other brain injuries such as intraventricular hemorrhage and periventricular leukomalacia. The review emphasizes the enhanced sensitivity of diffusion-weighted imaging (DWI) sequences in detecting early ischemic injury in this fragile group, facilitating more timely diagnosis compared to conventional imaging. However, challenges remain, particularly given the difficulty in performing MRI scans in critically ill preterm neonates and the variability in imaging protocols across centers. This underscores a pressing need for standardized neuroimaging guidelines to optimize stroke detection and monitoring in this demographic.

While some risk factors for PAIS and CSVT in preterm infants overlap with those in term neonates, the review draws attention to a constellation of prematurity-related complications uniquely amplifying vulnerability. Prolonged mechanical ventilation, often necessary for respiratory support in preterm infants, raises the risk of systemic inflammation and fluctuating cerebral perfusion, thereby setting the stage for ischemic injury. Additionally, postoperative states—especially following procedures such as patent ductus arteriosus ligation or necrotizing enterocolitis surgeries—introduce hemodynamic instability and prothrombotic conditions that were prevalent in the reviewed cases. These associations highlight the intricate interplay between medical interventions, systemic instability, and brain injury in preterm neonates.

Perhaps most distressingly, the neurodevelopmental outcomes emerging from PAIS and CSVT in preterm infants reflect substantial morbidity and mortality. The synthesis reveals alarmingly high rates of neurologic impairment, encompassing motor deficits consistent with cerebral palsy, cognitive delays, and epilepsy. Mortality rates were notably pronounced in CSVT cases, consistent with the severity of venous outflow obstruction and secondary complications such as extensive hemorrhagic infarctions. These grim outcomes accentuate the critical need for early recognition and effective interventions to mitigate long-term disability in this highly vulnerable group.

The comprehensive nature of this review also exposes significant knowledge gaps, particularly the paucity of large-scale, controlled studies focusing exclusively on the preterm population. Existing literature is fragmented, often limited by small sample sizes and heterogeneity in study design, which complicates the formulation of evidence-based guidelines. The authors advocate for multicenter collaborations and prospective cohort studies that can better elucidate causal pathways, refine prognostic markers, and evaluate therapeutic modalities tailored to the preterm brain’s unique physiology and injury mechanisms.

Prevention emerges as a pivotal theme, yet it remains largely aspirational at present. Given the intricate web of obstetric and neonatal risk factors, a multifaceted preventative approach is warranted. Optimizing maternal-fetal monitoring to detect conditions such as twin-to-twin transfusion syndrome, maintaining meticulous hemodynamic stability postnatally, and managing metabolic derangements like hypoglycemia are strategies highlighted in the review. However, translating these strategies into practice demands concerted efforts, including heightened clinical awareness and resource allocation.

Early diagnosis, integral to improving outcomes, faces hurdles due to the often subtle or nonspecific clinical presentation of stroke in preterm neonates. Seizures, apnea, and hypotonia may be attributed to a spectrum of neonatal conditions, delaying suspicion for cerebrovascular injury. The review underscores the potential of integrating neuroimaging protocols with close clinical monitoring to enhance early detection. Moreover, advances in cerebral near-infrared spectroscopy and biomarkers hold promise for non-invasive, bedside assessment to flag evolving cerebral ischemia before irreversible injury occurs.

Therapeutic options for PAIS and CSVT in preterm infants remain limited and are fraught with uncertainties regarding safety and efficacy. Anticoagulation, a mainstay in CSVT treatment in older children and adults, is challenging in preterm neonates due to bleeding risks and immature hemostatic systems. The review calls for carefully designed clinical trials to evaluate anticoagulation regimens, thrombolysis, and neuroprotective agents, emphasizing that therapeutic advances must balance efficacy with the delicate vulnerability of the developing brain.

This systematic review by van Oldenmark and colleagues thus represents a critical milestone in neonatal neurology research, emphasizing that preterm infants afflicted by PAIS and CSVT comprise a unique subset with distinct epidemiologic profiles, risks, and outcomes. Recognition of these nuances carries profound implications for clinical care pathways, research priorities, and health policy. As neonatal intensive care advances and survival of the smallest preemies improves, the imperative to mitigate devastating neurological sequelae has never been greater.

In sum, this landmark synthesis compels the neonatal and pediatric neurology communities to galvanize efforts toward comprehensive, multidisciplinary approaches encompassing prevention, refined diagnostics, and innovative therapies. Only through sustained scientific inquiry and translational advances can we hope to improve the fragile neurological futures of preterm infants confronted by these insidious cerebrovascular insults.

Subject of Research:
Perinatal arterial ischemic stroke (PAIS) and cerebral sinovenous thrombosis (CSVT) in preterm neonates

Article Title:
Perinatal arterial ischemic stroke (PAIS) and neonatal cerebral sinovenous thrombosis (CSVT) in the preterm neonate: a systematic review

Article References:
van Oldenmark, B.O., van Steenis, A., van der Aa, N.E. et al. Perinatal arterial ischemic stroke (PAIS) and neonatal cerebral sinovenous thrombosis (CSVT) in the preterm neonate: a systematic review. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-04800-3

Image Credits: AI Generated

DOI: 12 February 2026